Long-term treatment with Ofev (nintedanib) safely and effectively slows lung function decline in adults with interstitial lung disease…
Articles by Marta Figueiredo, PhD
Ofev (nintedanib) slows clinically relevant disease progression in adults with interstitial lung disease (ILD) associated with systemic sclerosis (SSc-ILD), according…
The American College of Rheumatology Combined Response Index in diffuse cutaneous systemic sclerosis (ACR CRISS) appears to be a consistent and…
Emerald Health Pharmaceuticals has launched a clinical trial evaluating EHP-101, its investigational cannabidiol-derived therapy, in adults with…
Higher-than-normal blood levels of squamous cell carcinoma antigen 1 (SCCA1), a pro-fibrotic protein, are associated with a greater risk…
A panel of experts in Europe defined a set of recommendations for the diagnosis and management of interstitial lung…
Privigen — an approved therapy for a range of immune-related conditions — has been granted orphan drug designation…
The levels of an immunosuppressive protein called human leukocyte antigen G (HLA-G) are significantly higher in the immune cells…
Early detection of bowel perforation in scleroderma patients who are experiencing abdominal symptoms may be lifesaving, according to a case report.
Treatment with Ofev (nintedanib) slows the rate of lung function decline in people with autoimmune-related interstitial lung diseases…